Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 3, pp. S69 - S69
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 2, pp. S161 - S161
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S297 - S298
Journal Article
Journal of Pain and Symptom Management, ISSN 0885-3924, 2010, Volume 39, Issue 2, pp. 346 - 347
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 3, pp. S402 - S403
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S344 - S345
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S343 - S344
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 2, pp. S158 - S159
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 2, pp. S25 - S26
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 2, pp. S221 - S222
Journal Article
American Journal of Hematology, ISSN 0361-8609, 03/2016, Volume 91, Issue 3, pp. 322 - 329
For adults with Philadelphia chromosome‐negative (Ph−) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell...
YOUNG-ADULTS | REDUCED-INTENSITY | DOSE INTENSIFICATION | 2ND COMPLETE REMISSION | CONVENTIONAL CONSOLIDATION/MAINTENANCE CHEMOTHERAPY | HEMATOPOIETIC-CELL TRANSPLANTATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | UNRELATED DONORS | GROUP-B | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Bone Marrow Transplantation - methods | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - mortality | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - therapy | Transplantation, Homologous | Dose-Response Relationship, Drug | Young Adult | Disease-Free Survival | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Adult | Female | Remission Induction - methods | Hematopoietic Stem Cell Transplantation - methods | Pediatrics | Chemotherapy | Leukemia | Adults | Children | Comparative analysis | Health aspects | Cancer | Hematopoietic Stem Cell Transplantation | Acute Lymphoblastic | Clinical Trials
YOUNG-ADULTS | REDUCED-INTENSITY | DOSE INTENSIFICATION | 2ND COMPLETE REMISSION | CONVENTIONAL CONSOLIDATION/MAINTENANCE CHEMOTHERAPY | HEMATOPOIETIC-CELL TRANSPLANTATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | UNRELATED DONORS | GROUP-B | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Bone Marrow Transplantation - methods | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - mortality | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - therapy | Transplantation, Homologous | Dose-Response Relationship, Drug | Young Adult | Disease-Free Survival | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Adult | Female | Remission Induction - methods | Hematopoietic Stem Cell Transplantation - methods | Pediatrics | Chemotherapy | Leukemia | Adults | Children | Comparative analysis | Health aspects | Cancer | Hematopoietic Stem Cell Transplantation | Acute Lymphoblastic | Clinical Trials
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 11, pp. 1729 - 1736
Abstract The poor prognosis for patients with diffuse large B cell lymphoma (DLBCL) who relapse within 1 year of initial diagnosis after first-line...
Hematology, Oncology and Palliative Medicine | Non-Hodgkin lymphoma | Early failure | Autologous transplantation | High-dose therapy | Rituximab | Aggressive lymphoma | Diffuse large B cell lymphoma | INTERMEDIATE-GRADE | CONDITIONING REGIMENS | TRIAL MINT GROUP | CHEMOTHERAPY PLUS RITUXIMAB | GERMINAL-CENTER | Diffuse large Bcell lymphoma | CHOP-LIKE CHEMOTHERAPY | BONE-MARROW TRANSPLANTATION | Diffuse large B cell lymphoma | NON-HODGKINS-LYMPHOMA | SALVAGE THERAPY | IMMUNOLOGY | TRANSPLANTATION | HEMATOLOGY | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Treatment Outcome | Disease Progression | Young Adult | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Treatment Failure | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Cohort Studies | Chemotherapy | Analysis | Immunotherapy | Lymphomas | Transplantation | Hematopoietic stem cells | Cancer | Basic Medicine | Medical and Health Sciences | Hematology | Medicin och hälsovetenskap | Immunologi inom det medicinska området | Klinisk medicin | Clinical Medicine | Hematologi | Medicinska och farmaceutiska grundvetenskaper | Immunology in the medical area
Hematology, Oncology and Palliative Medicine | Non-Hodgkin lymphoma | Early failure | Autologous transplantation | High-dose therapy | Rituximab | Aggressive lymphoma | Diffuse large B cell lymphoma | INTERMEDIATE-GRADE | CONDITIONING REGIMENS | TRIAL MINT GROUP | CHEMOTHERAPY PLUS RITUXIMAB | GERMINAL-CENTER | Diffuse large Bcell lymphoma | CHOP-LIKE CHEMOTHERAPY | BONE-MARROW TRANSPLANTATION | Diffuse large B cell lymphoma | NON-HODGKINS-LYMPHOMA | SALVAGE THERAPY | IMMUNOLOGY | TRANSPLANTATION | HEMATOLOGY | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Treatment Outcome | Disease Progression | Young Adult | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Treatment Failure | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Cohort Studies | Chemotherapy | Analysis | Immunotherapy | Lymphomas | Transplantation | Hematopoietic stem cells | Cancer | Basic Medicine | Medical and Health Sciences | Hematology | Medicin och hälsovetenskap | Immunologi inom det medicinska området | Klinisk medicin | Clinical Medicine | Hematologi | Medicinska och farmaceutiska grundvetenskaper | Immunology in the medical area
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 01/2019, Volume 25, Issue 1, pp. 73 - 85
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF)...
Graft-versus-host disease prophylaxis | Allogeneic hematopoietic cell transplantation | Reduced-intensity conditioning | Calcineurin inhibitor Tacrolimus | Cyclosporine | Mycophenolate mofetil | Methotrexate | COMPARING METHOTREXATE | BONE-MARROW | IMMUNOLOGY | TRANSPLANTATION | TRIAL | GVHD PROPHYLAXIS | STEM-CELL TRANSPLANTATION | TACROLIMUS | HEMATOLOGY | BLOOD
Graft-versus-host disease prophylaxis | Allogeneic hematopoietic cell transplantation | Reduced-intensity conditioning | Calcineurin inhibitor Tacrolimus | Cyclosporine | Mycophenolate mofetil | Methotrexate | COMPARING METHOTREXATE | BONE-MARROW | IMMUNOLOGY | TRANSPLANTATION | TRIAL | GVHD PROPHYLAXIS | STEM-CELL TRANSPLANTATION | TACROLIMUS | HEMATOLOGY | BLOOD
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 10, pp. 1746 - 1753
Abstract The purpose of this study was to analyze the impact of graft-versus-host disease (GVHD) on the relapse rate of different lymphoma subtypes after...
Hematology, Oncology and Palliative Medicine | Graft-versus-host disease | Lymphoma | EUROPEAN GROUP | IMMUNOLOGY | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | HODGKINS-LYMPHOMA | BONE-MARROW TRANSPLANT | REMISSIONS | INFUSIONS | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | REGISTRY | Recurrence | Lymphoma - physiopathology | Graft vs Host Disease - complications | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Lymphoma - mortality | Young Adult | Lymphoma - drug therapy | Lymphoma - therapy | Adult | Female | Lymphoma - pathology | Transplantation Conditioning - methods | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Histocompatibility | Care and treatment | Relapse | Lymphomas | Political corruption | Analysis | Diseases | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | Klinisk medicin
Hematology, Oncology and Palliative Medicine | Graft-versus-host disease | Lymphoma | EUROPEAN GROUP | IMMUNOLOGY | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | HODGKINS-LYMPHOMA | BONE-MARROW TRANSPLANT | REMISSIONS | INFUSIONS | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | REGISTRY | Recurrence | Lymphoma - physiopathology | Graft vs Host Disease - complications | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Lymphoma - mortality | Young Adult | Lymphoma - drug therapy | Lymphoma - therapy | Adult | Female | Lymphoma - pathology | Transplantation Conditioning - methods | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Histocompatibility | Care and treatment | Relapse | Lymphomas | Political corruption | Analysis | Diseases | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 04/2018, Volume 24, Issue 4, pp. 726 - 733
Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT)....
Total body irradiation | Allogeneic transplant | Busulfan | Acute lymphoblastic leukemia | Transplantation | Hematology | LONG-TERM | PREPARATIVE REGIMEN | IMMUNOLOGY | 1ST COMPLETE REMISSION | FLUDARABINE | WORKING PARTY | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | MARROW-TRANSPLANTATION | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EXPOSURE | BLOOD | Whole-Body Irradiation | Follow-Up Studies | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Survival Rate | Busulfan - administration & dosage | Disease-Free Survival | Administration, Intravenous | Allografts | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Adolescent | Adult | Female | Transplantation Conditioning | Adults | Acute lymphocytic leukemia | Analysis | Resveratrol
Total body irradiation | Allogeneic transplant | Busulfan | Acute lymphoblastic leukemia | Transplantation | Hematology | LONG-TERM | PREPARATIVE REGIMEN | IMMUNOLOGY | 1ST COMPLETE REMISSION | FLUDARABINE | WORKING PARTY | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | MARROW-TRANSPLANTATION | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EXPOSURE | BLOOD | Whole-Body Irradiation | Follow-Up Studies | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Survival Rate | Busulfan - administration & dosage | Disease-Free Survival | Administration, Intravenous | Allografts | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Adolescent | Adult | Female | Transplantation Conditioning | Adults | Acute lymphocytic leukemia | Analysis | Resveratrol
Journal Article
16.
Full Text
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 2, pp. 248 - 257
Abstract The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML...
Hematology, Oncology and Palliative Medicine | Allogeneic transplantation | Acute myeloid leukemia | Monosomal karyotype | Myelodysplastic syndrome | INTERNATIONAL BLOOD | IMMUNOLOGY | PROGNOSTIC VALUE | CYTOGENETICS | CONDITIONING REGIMEN | TRANSPLANTATION | REDUCED-INTENSITY | IMPACT | LEUKEMIA WORKING PARTY | SCORING SYSTEM | HEMATOLOGY | MYELODYSPLASTIC SYNDROMES | Humans | Middle Aged | Child, Preschool | Infant | Male | Treatment Outcome | Young Adult | Myelodysplastic Syndromes - therapy | Adolescent | Myelodysplastic Syndromes - mortality | Adult | Female | Aged | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Child | Karyotype | Transplantation | Chromosomes | Analysis | Hematopoietic stem cells | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | Klinisk medicin
Hematology, Oncology and Palliative Medicine | Allogeneic transplantation | Acute myeloid leukemia | Monosomal karyotype | Myelodysplastic syndrome | INTERNATIONAL BLOOD | IMMUNOLOGY | PROGNOSTIC VALUE | CYTOGENETICS | CONDITIONING REGIMEN | TRANSPLANTATION | REDUCED-INTENSITY | IMPACT | LEUKEMIA WORKING PARTY | SCORING SYSTEM | HEMATOLOGY | MYELODYSPLASTIC SYNDROMES | Humans | Middle Aged | Child, Preschool | Infant | Male | Treatment Outcome | Young Adult | Myelodysplastic Syndromes - therapy | Adolescent | Myelodysplastic Syndromes - mortality | Adult | Female | Aged | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Child | Karyotype | Transplantation | Chromosomes | Analysis | Hematopoietic stem cells | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3141 - 3149
BACKGROUND Race/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell...
myeloma | transplantation utilization | Hispanic | blacks | MAINTENANCE | THERAPY | DISPARITIES | ONCOLOGY | RACE | OUTCOMES | ACCESS | Ethnic Groups - statistics & numerical data | United States | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Humans | Middle Aged | Healthcare Disparities - ethnology | European Continental Ancestry Group - statistics & numerical data | Hispanic Americans - statistics & numerical data | Male | Transplantation, Autologous - statistics & numerical data | Young Adult | African Americans - statistics & numerical data | Multiple Myeloma - pathology | Multiple Myeloma - therapy | Adolescent | Adult | Female | Registries | Aged | Neoplasm Staging | Care and treatment | Usage | Hispanic Americans | Multiple myeloma | Transplantation | Health aspects | Hematopoietic stem cells | Autografts | Transplants & implants | Stem cell transplantation | Blacks | Minority & ethnic groups | Patients | Epidemiology | Hemopoiesis | Incidence | Ethnicity | Utilization | Grafts | Race | Melphalan | Stem cells | Target markets | Conditioning | Hispanics | Age | Cancer | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cancer and Oncology | Klinisk medicin | Cancer och onkologi
myeloma | transplantation utilization | Hispanic | blacks | MAINTENANCE | THERAPY | DISPARITIES | ONCOLOGY | RACE | OUTCOMES | ACCESS | Ethnic Groups - statistics & numerical data | United States | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Humans | Middle Aged | Healthcare Disparities - ethnology | European Continental Ancestry Group - statistics & numerical data | Hispanic Americans - statistics & numerical data | Male | Transplantation, Autologous - statistics & numerical data | Young Adult | African Americans - statistics & numerical data | Multiple Myeloma - pathology | Multiple Myeloma - therapy | Adolescent | Adult | Female | Registries | Aged | Neoplasm Staging | Care and treatment | Usage | Hispanic Americans | Multiple myeloma | Transplantation | Health aspects | Hematopoietic stem cells | Autografts | Transplants & implants | Stem cell transplantation | Blacks | Minority & ethnic groups | Patients | Epidemiology | Hemopoiesis | Incidence | Ethnicity | Utilization | Grafts | Race | Melphalan | Stem cells | Target markets | Conditioning | Hispanics | Age | Cancer | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cancer and Oncology | Klinisk medicin | Cancer och onkologi
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 03/2018, Volume 53, Issue 3, pp. 307 - 314
Despite a high prevalence of sleep disruption among hematopoietic cell transplant (HCT) recipients, relatively little research has investigated its...
MULTIPLE-MYELOMA | BONE-MARROW-TRANSPLANTATION | CIRCADIAN-RHYTHMS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | TRANSPLANTATION | BREAST-CANCER | ONCOLOGY | COGNITIVE-BEHAVIORAL THERAPY | QUALITY-OF-LIFE | HEMATOLOGY | INSOMNIA SEVERITY INDEX | STRESS REDUCTION | MATCHED CONTROLS | Humans | Middle Aged | Self Report | Actigraphy | Male | Neoplasms - psychology | Sleep Wake Disorders - psychology | Neoplasms - complications | Neoplasms - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Transplantation, Autologous - adverse effects | Female | Aged | Hematopoietic Stem Cell Transplantation - psychology | Sleep Wake Disorders - etiology | Hematopoietic agents | Usage | Transplantation | Analysis | Hematopoietic stem cells | Autografts | Transplants & implants | Cognitive ability | Patients | Sleep deprivation | Hemopoiesis | Fear | Sleep | Behavior | Disruption | Sleep and wakefulness | Cancer | sleep | distress | hematopoietic cell transplant | actigraphy | neoplasm
MULTIPLE-MYELOMA | BONE-MARROW-TRANSPLANTATION | CIRCADIAN-RHYTHMS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | TRANSPLANTATION | BREAST-CANCER | ONCOLOGY | COGNITIVE-BEHAVIORAL THERAPY | QUALITY-OF-LIFE | HEMATOLOGY | INSOMNIA SEVERITY INDEX | STRESS REDUCTION | MATCHED CONTROLS | Humans | Middle Aged | Self Report | Actigraphy | Male | Neoplasms - psychology | Sleep Wake Disorders - psychology | Neoplasms - complications | Neoplasms - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Transplantation, Autologous - adverse effects | Female | Aged | Hematopoietic Stem Cell Transplantation - psychology | Sleep Wake Disorders - etiology | Hematopoietic agents | Usage | Transplantation | Analysis | Hematopoietic stem cells | Autografts | Transplants & implants | Cognitive ability | Patients | Sleep deprivation | Hemopoiesis | Fear | Sleep | Behavior | Disruption | Sleep and wakefulness | Cancer | sleep | distress | hematopoietic cell transplant | actigraphy | neoplasm
Journal Article